| Literature DB >> 21186794 |
Martina Bazzaro1, Ravi K Anchoori, Mohana Krishna R Mudiam, Olga Issaenko, Srinivas Kumar, Balasubramanyam Karanam, Zhenhua Lin, Rachel Isaksson Vogel, Riccardo Gavioli, Federica Destro, Valeria Ferretti, Richard B S Roden, Saeed R Khan.
Abstract
Proteasome inhibitors have potential for the treatment of cervical cancer. We describe the synthesis and biological characterization of a new series of 1,3-diphenylpropen-1-one (chalcone) based derivatives lacking the boronic acid moieties of the previously reported chalcone-based proteasome inhibitor 3,5-bis(4-boronic acid benzylidene)-1-methylpiperidin-4-one and bearing a variety of amino acid substitutions on the amino group of the 4-piperidone. Our lead compound 2 (RA-1) inhibits proteasomal activity and has improved dose-dependent antiproliferative and proapoptotic properties in cervical cancer cells containing human papillomavirus. Further, it induces synergistic killing of cervical cancer cell lines when tested in combination with an FDA approved proteasome inhibitor. Exploration of the potential mechanism of proteasomal inhibition by our lead compound using in silico docking studies suggests that the carbonyl group of its oxopiperidine moiety is susceptible to nucleophilic attack by the γ-hydroxythreonine side chain within the catalytic sites of the proteasome.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21186794 PMCID: PMC3204583 DOI: 10.1021/jm100589p
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446